Scientific Presentations

The data presented in the publications, poster and oral presentations are from investigational products that are not approved by any regulatory authority and are being made available only to investors and potential investors.

GVAX Immunotherapy for Prostate Cancer

2008 ASCO Poster Presentation
Expanded Phase 1 Combination Trial of GVAX Immunotherapy for Prostate Cancer and Ipilimumab in Patients with Metastatic Hormone-Refractory Prostate Cancer (mHRPC) W. R. Gerritsen, A. J. van den Eertwegh, T. D. de Gruijl, H.P. Van den Berg, R. J. Scheper1, N. Sacks, I. Lowy, E. Stankevich, K. Hege

2008 AACR Poster Presentation
Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer treated with GVAX immunotherapy for prostate cancer and ipilimumab
Satoshi Wada, Kiyoshi Yoshimura, Edward L. Hipkiss, Timothy Harris, Hung-Rong Yen, Monica V. Goldberg, Joseph F. Grosso, Derese Getnet, George Netto, Robert Anders, Angelo M. DeMarzo, Drew M. Pardoll, Charles G. Drake

2008 ASCO GU Poster Presentation
Identification of Antibody Responses Induced in Patient with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Treated with GVAX Immunotherapy for Prostate Cancer.
T. Harding1, M. Nguyen1, K. Koprivnikar1, G. Huan-Tu1, N. Sacks1, E. J. Small2, K. Jooss1 1Cell Genesys, Inc., South San Francisco, CA 94080; 2University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA 94143

2006 ASCO Prostate Cancer Symposium Poster Presentation
Analysis of Prognostic Variables in Phase 2 Trials of GVAX Immunotherapy for Prostate Cancer in Metastatic Hormone Refractory Prostate Cancer.
Eric J. Small, M.D., Celestia Higano, M.D.David Smith, M.D., John Corman, M.D., Christopher Steidle, M.D., Marc Gittelman, M.D., Gary Hudes, M.D., Natalie Sacks, M.D., and Jonathan W. Simons, M.D.

2007 AACR Oral Presentation
Identification of antibody responses induced in patients with metastatic hormone-refractory prostate cancer (HRPC) treated with a GM-CSF-transduced allogeneic prostate cancer immunotherapy.
Thomas C. Harding, Minh C. Nguyen, Kathryn E. Koprivnikar, Guang Huan-Tu, Karin U. Jooss

GVAX Immunotherapy for Pancreatic Cancer

* 2007 ASCO Oral Poster Presentation
A safety and efficacy trial of lethally irradiated pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. D. Laheru, J. Herman, E. Sugar, E. Lutz, B. Biedrzycki, C. Yeo, S. Solt, , B. Onners, I. Tartakovsky, R. Abrams, R. Donehower, J. Winter, R. Hruban, E. Jaffee.

GVAX Immunotherapy for Leukemia

* 2006 ASCO Oral Presentation
K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients with residual disease on imatinib mesylate (IM).
B Smith, Y.L. Kasamon, C.B. Miller, C. Chia, G. Gocke, J. Kowalski, I. Tartakovsky, B. Biedrzycki, R. J. Jones, K. Hege, H. I. Levitsky.

2005 ASCO Poster Presentation
Vaccine-associated Immune and WT-1 Responses are Associated with Better Relapse-Free Survival in Patients with AML in Remission Treated with a GM-CSF Secreting Leukemia Vaccine and Autologous Stem Cell Transplant.
Ivan Borello, Hyam Levitsky; Lloyd Damon, Charles Linker; Daniel DeAngelo, Edwin Alyea; Wendy Stock, Dorie Sher; Amy Donnelly, Kristen Hege.

CG0070 Oncolytic Virus Therapy

2008 AUA Oral Presentation
Phase 1 Study of Multi-Dose Administration of Intravesical CG0070 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
James M. McKiernan, Donald L. Lamm, Maxwell V. Meng, John J. Nemunaitis, James C. Arseneau, Joe Stephenson, James M. Burke, Junko Aimi, Daniel J. Maslyar

*Includes data from studies performed under an investigator-sponsored IND